OncoGenex Pharmaceuticals Inc.
1522 217th Place SE
About OncoGenex Pharmaceuticals Inc.OncoGenex Pharmaceuticals is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address unmet needs in the treatment of cancer. We have a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development.
We currently have five product candidates in development: OGX-011, OGX-427, SN2310, CSP-9222 and OGX-225. Three of the products are in clinical development.
We have conducted five phase 2 clinical trials to evaluate the ability of OGX-011 to enhance the effects of therapy in prostate, non-small cell lung and breast cancer.
In December 2009, we announced that we entered into a Collaboration and License Agreement with Teva Pharmaceutical Industries, for the development and global commercialization of OGX-011. In connection with the Collaboration Agreement, OncoGenex and Teva developed a Clinical Development Plan under which the following three phase 3 clinical trials will be initiated:
• a phase 3 clinical trial of OGX-011 in approximately 300 patients with second-line castrate resistant prostate cancer; • a phase 3 clinical trial of OGX-011 in approximately 800 patients with first-line castrate resistant prostate cancer; and • a phase 3 clinical trial of OGX-011 in at least 700 patients with first-line non-small cell lung cancer.
We have reached an agreement with the U.S. Food and Drug Administration (FDA) on the design of two Phase 3 registration trials of OGX-011 in patients with CRPC via the Special Protocol Assessment (SPA) process.
Learn more about OncoGenex at www.oncogenex.com
US Operations: Suite 100, 1522 217th Place SE, Bothell, WA 98021. Phone (425) 686-1500
Canadian Operations: Suite 400 – 1001 West Broadway, Vancouver, BC V6H 4B1. Tel: (604) 736-3678
Founders: Martin Gleave and Scott Daniel Cormack
CEO and Founder: Scott Cormack
CMO (Medical): Cindy Jacobs
CFO: John Bencich
Please click here for.
Please click here for clinical trial information.
Tweets by OncoGenex
208 articles with OncoGenex Pharmaceuticals Inc.
Achieve Life Science And OncoGenex Announce Form S-4 Registration Statement Declared Effective By SEC
Achieve Life Science And OncoGenex Announce Cytisine Symposium At The Annual Society For Research In Nicotine And Tobacco Conference ("SRNT")
Achieve Life Science And OncoGenex Announce Strategic Collaboration With The OncoGenex To Advance The Development Of Cytisine For Smoking Cessation
OncoGenex Release: Data Support Continued Exploration Of Hsp27 Inhibition In Bladder And Prostate Cancers
OncoGenex Announces Phase II Apatorsen Data For Two Clinical Trials Presented At The OncoGenex 2017 Genitourinary Cancers Symposium
OncoGenex Announces Positive Survival Results From Apatorsen Phase 2 Borealis-2 Trial In Metastatic Bladder Cancer
OncoGenex Announces Results From the Phase III ENSPIRIT Trial of Custirsen in Non-Small Cell Lung Cancer